RxDoctor Payments Data

Cecil Vandenabeele, PA

Physician Assistant · Olathe, KSNPI 1396827267

Payments from drug & device makers

$1,928in general payments, 2019–2025

Across 148 payments — averaging $13.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$453
  • Novo Nordisk$351
  • Insulet Corporation$184
  • Dexcom, Inc.$143
  • Lilly USA, LLC$142
  • Xeris Pharmaceuticals, Inc.$139
  • plus $516 from 12 others

What the payments were for

  • Food & beverage$1,91699%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,928 in reported general payments places this provider in the 80th percentile of 1,016 physician assistant providers in Kansas.

See all physician assistant providers in Kansas

Medicare billing

Part B allowed, 2024
$46,823
Medicare patients
133
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$164,571
MounjaroTirzepatide135$150,010
JardianceEmpagliflozin76$85,040
Humulin R U-500 KwikpenInsulin Regular, Human43$81,953
Tresiba Flextouch U-100Insulin Degludec104$63,156
TrulicityDulaglutide31$37,338
Novolog FlexpenInsulin Aspart139$37,251
Tresiba Flextouch U-200Insulin Degludec34$35,047
Humalog Kwikpen U-100Insulin Lispro132$34,080
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog58$32,995
FarxigaDapagliflozin Propanediol31$29,031
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$27,631
RybelsusSemaglutide26$23,175
Fiasp FlextouchInsulin Aspart (Niacinamide)21$22,585
Lantus SolostarInsulin Glargine,hum.Rec.Anlog161$21,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$142$191,771179 claims
Novo NordiskOzempic, Rybelsus$351$187,746165 claims
Boehringer IngelheimJardiance, Tradjenta$32$105,31999 claims
AbbVieSynthroid$62$1,79725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,016 physician assistant providers in Kansas.

Other physician assistant in Olathe

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →